<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d360aaf2-0e56-4626-8bcf-7d480909a15a"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use EMRELIS safely and effectively. See full prescribing information for EMRELIS.<br/> <br/>EMRELIS™ (telisotuzumab vedotin-tllv) for injection, for intravenous use<br/>Initial U.S. Approval: 2025<br/>
   </title>
   <effectiveTime value="20250514"/>
   <setId root="bc04f980-3957-4e35-ab81-8ec2ffe87215"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="078458370" root="1.3.6.1.4.1.519.1"/>
            <name>AbbVie Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="cd994e41-856d-4def-9f88-3e08d6dbe76a"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250515"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-1044" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Telisotuzumab Vedotin</name>
                        <formCode code="C42957" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Telisotuzumab Vedotin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="976X9VXC3Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TELISOTUZUMAB VEDOTIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="976X9VXC3Z" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TELISOTUZUMAB VEDOTIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="70.0"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1044-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250514"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761384" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250514"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0074-1055" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Telisotuzumab Vedotin</name>
                        <formCode code="C42957" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Telisotuzumab Vedotin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="976X9VXC3Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TELISOTUZUMAB VEDOTIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="976X9VXC3Z" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TELISOTUZUMAB VEDOTIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="70.0"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0074-1055-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250514"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761384" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" displayName="BLA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250514"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1__INDICATIONS">
               <id root="b65e2135-ec89-43af-ad50-6fa38e2e58a4"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1  INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test<content styleCode="italics"> [see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_1_Patient_Selection">2.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>, who have received a prior systemic therapy<content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response<content styleCode="bold"> </content>(DOR) <content styleCode="italics">[see Clinical Studies (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_14__CLINICAL">14</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. (<linkHtml href="#_1__INDICATIONS">1</linkHtml>)</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). (<linkHtml href="#_1__INDICATIONS">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="f8e9d85d-426a-410a-b699-98a2436b26ff"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2  DOSAGE AND ADMINISTRATION </content>
               </title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">For intravenous infusion only. </content>(<linkHtml href="#_2_5_Preparation_and">2.5</linkHtml>)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage of EMRELIS is 1.9 mg/kg administered intravenously every 2 weeks until disease progression or unacceptable toxicity. (<linkHtml href="#_2_2_Recommended_Dosage">2.2</linkHtml>)<br/>
                           </item>
                           <item>Reconstitute and further dilute EMRELIS prior to intravenous infusion. (<linkHtml href="#_2_5_Preparation_and">2.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Patient_Selection">
                     <id root="26378388-b63b-4c41-8cf6-b7bf47779669"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Patient Selection</content>
                     </title>
                     <text>
                        <paragraph>Select patients for treatment with EMRELIS based on the presence of high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining] in patients with non-squamous NSCLC <content styleCode="italics">[see Indications and Usage (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_1__INDICATIONS">1</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14__CLINICAL">14</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Information on FDA-approved tests for the detection of high c-Met protein overexpression is available at: http://www.fda.gov/CompanionDiagnostics.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Recommended_Dosage">
                     <id root="fc9cc2d7-9f88-4708-87d0-aa32f6edb959"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Recommended Dosage</content>
                     </title>
                     <text>
                        <paragraph>The recommended dosage of EMRELIS is 1.9 mg/kg (up to a maximum of 190 mg for patients greater than or equal to 100 kg) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Dosage_Modifications">
                     <id root="d3abbff8-1282-4cdc-88e2-8e8f127f57bd"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Dosage Modifications </content>
                        <content styleCode="bold">for Adverse Reactions </content>
                     </title>
                     <text>
                        <paragraph>The recommended dose reductions for adverse reactions are provided in Table 1.</paragraph>
                        <table>
                           <caption>Table 1. Recommended Dose Reductions</caption>
                           <col width="192"/>
                           <col width="443"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dose Reduction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Recommended</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">First </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.6 mg/kg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Second </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.3 mg/kg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Third </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 mg/kg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2">Permanently discontinue EMRELIS in patients who are unable to tolerate 1 mg/kg.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The recommended dosage modifications of EMRELIS for adverse reactions are provided in Table 2.</paragraph>
                        <table>
                           <caption>Table 2. EMRELIS Dosage Modifications and Management for Adverse Reactions</caption>
                           <col width="291"/>
                           <col width="138"/>
                           <col width="290"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Severity</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dosage Modification</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Peripheral Neuropathy<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_1_Peripheral_Neuropathy">5.1</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 2 or 3</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS until recovery to Grade ≤1.<br/>
                                       </item>
                                       <item>Resume EMRELIS at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule ">Permanently discontinue EMRELIS.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Interstitial Lung Disease (ILD)/Pneumonitis<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_2_Interstitial_Lung">5.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 1</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS and consider corticosteroids as soon as ILD/pneumonitis is suspected.<br/>
                                       </item>
                                       <item>Resume EMRELIS upon radiographic resolution.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Grade ≥2</td>
                                 <td styleCode="Toprule Lrule Rrule ">Permanently discontinue EMRELIS.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Keratitis<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_3_Ocular_Surface">5.3</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 2</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS.<br/>
                                       </item>
                                       <item>Refer patients to an eye care professional for an ophthalmic examination and treatment (e.g., lubricating and/or steroidal eye drops).<br/>
                                       </item>
                                       <item>Resume EMRELIS at the same dose at the discretion of the healthcare provider.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 3 or 4</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Refer patients to an eye care professional for an ophthalmic examination and treatment (e.g., lubricating and/or steroidal eye drops).<br/>
                                       </item>
                                       <item>Permanently discontinue EMRELIS.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Infusion-Related Reactions (IRR)<br/>
                                    <content styleCode="italics">[see Warnings and Precautions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_5_4_Infusion_Related_Reactions">5.4</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 1-3</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Interrupt EMRELIS infusion and administer supportive treatment.<br/>
                                       </item>
                                       <item>Resume the infusion at a 50% rate reduction. Increase infusion rate as tolerated for subsequent doses.<br/>
                                       </item>
                                       <item>For patients who experience an IRR, administer premedications prior to all future doses <content styleCode="italics">(see Table </content>
                                          <content styleCode="italics">3</content>
                                          <content styleCode="italics">).</content>
                                       </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue EMRELIS. <br/>
                                       </item>
                                       <item>Administer supportive treatment.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Peripheral Edema<br/>
                                    <content styleCode="italics">[see Adverse Reactions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade ≥2</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="underline">First occurrence</content>
                                    <br/>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS until recovery to Grade ≤1.<br/>
                                       </item>
                                       <item>Resume EMRELIS at the same dose level.</item>
                                    </list>
                                    <content styleCode="underline">Subsequent occurrence</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS until recovery to Grade ≤1.<br/>
                                       </item>
                                       <item>Resume EMRELIS at the next lower dose level. </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Other <br/>Adverse Reactions<br/>
                                    <content styleCode="italics">[see Adverse Reactions (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                                    </content>
                                    <content styleCode="italics">)]</content>
                                    <br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 3</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="underline">First occurrence</content>
                                    <br/>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS until recovery to Grade ≤1.<br/>
                                       </item>
                                       <item>Resume EMRELIS at the same dose.</item>
                                    </list>
                                    <content styleCode="underline">Subsequent occurrence</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Withhold EMRELIS until recovery to Grade ≤1.<br/>
                                       </item>
                                       <item>Resume EMRELIS at the next lower dose level.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 4</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Permanently discontinue EMRELIS.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <sup>a</sup>Adverse reactions were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_4_Recommended_Premedications">
                     <id root="2c784e20-6353-44d1-8546-a7be96753587"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold"> Recommended Premedications for Patients Who Experience Infusion-Related Reactions</content>
                     </title>
                     <text>
                        <paragraph>Table 3 contains the recommended premedications for patients who experience infusion-related reactions to EMRELIS, for subsequent infusions.</paragraph>
                        <table>
                           <caption>Table 3: Recommended Premedications for Patients Who Experience Infusion-Related Reactions</caption>
                           <col width="120"/>
                           <col width="162"/>
                           <col width="132"/>
                           <col width="132"/>
                           <col width="174"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Medication Class</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">E</content>
                                    <content styleCode="bold">xamples or equivalent</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dose</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Route of Administration</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dosing Window Prior to </content>
                                    <content styleCode="bold">EMRELIS</content>
                                    <content styleCode="bold"> Administration</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">H1 Antihistamine</td>
                                 <td styleCode="Toprule Lrule Rrule ">Diphenhydramine</td>
                                 <td styleCode="Toprule Lrule Rrule ">25 to 50 mg</td>
                                 <td styleCode="Toprule Lrule Rrule ">Intravenously or orally</td>
                                 <td styleCode="Toprule Lrule Rrule ">Administer 30-60 minutes prior to each infusion</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">H2 Antihistamine</td>
                                 <td styleCode="Toprule Lrule Rrule ">Famotidine</td>
                                 <td styleCode="Toprule Lrule Rrule ">20 mg</td>
                                 <td styleCode="Toprule Lrule Rrule ">Intravenously or orally </td>
                                 <td styleCode="Toprule Lrule Rrule ">Administer 30-60 minutes prior to each infusion</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Antipyretic</td>
                                 <td styleCode="Toprule Lrule Rrule ">Acetaminophen</td>
                                 <td styleCode="Toprule Lrule Rrule ">650 to 1,000 mg</td>
                                 <td styleCode="Toprule Lrule Rrule ">Intravenously or orally</td>
                                 <td styleCode="Toprule Lrule Rrule ">Administer 30-60 minutes prior to each infusion</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Glucocorticoid</td>
                                 <td styleCode="Toprule Lrule Rrule ">Methylprednisolone<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">125 mg or equivalent</td>
                                 <td styleCode="Toprule Lrule Rrule ">Intravenously</td>
                                 <td styleCode="Toprule Lrule Rrule ">Administer 30-60 minutes prior to each infusion</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_5_Preparation_and">
                     <id root="fb67f5be-b65e-4ae6-a7e3-ded9807ee209"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold"> Preparation and Administration</content>
                     </title>
                     <text>
                        <paragraph>EMRELIS contains a hazardous component. Follow applicable special handling and disposal procedures in accordance with local requirements.<sup>1</sup>
                        </paragraph>
                        <paragraph>Reconstitute and further dilute EMRELIS prior to intravenous infusion. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Reconstitution of Lyophilized </content>
                           <content styleCode="underline">EMRELIS</content>
                        </paragraph>
                        <paragraph>Before reconstitution, allow the vial to reach room temperature after removal of the vial from storage condition. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Calculate the recommended dose based on the patient’s weight to determine the number of vials needed. For patients weighing greater than or equal to 100 kg, use 190 mg dose <content styleCode="italics">[see Dosage and Administration (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#_2_2_Recommended_Dosage">2.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.<content styleCode="italics"> </content>More than one vial may be needed to achieve the calculated dose. <br/>
                           </item>
                           <item>Using a sterile syringe, slowly inject Sterile Water for Injection, using the volume provided in Table 4, into the EMRELIS vial containing the lyophilized powder, which has a whole or fragmented cake-like appearance. The reconstituted solution has a concentration of 20 mg/mL EMRELIS. </item>
                        </list>
                        <table>
                           <caption>Table 4. Reconstitution Volumes</caption>
                           <col width="132"/>
                           <col width="306"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Dose Vial</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Volume of Sterile Water for Injection required for reconstitution</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">20 mg vial</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom">1.1 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">100 mg vial</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom">5.2 mL</td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" styleCode="Disc">
                           <item>Swirl the vial gently until completely dissolved. Do not shake.<br/>
                           </item>
                           <item>Inspect the reconstituted solution for particulate matter and discoloration. The solution should appear clear to slightly opalescent and colorless to slightly yellow. Discard the vial if the reconstituted solution is discolored, is cloudy, or contains visible particulates.<br/>
                           </item>
                           <item>Use reconstituted EMRELIS immediately. If not used immediately, store the reconstituted EMRELIS vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution. Do not freeze.<br/>
                           </item>
                           <item>Each vial of EMRELIS is intended for one-time use only. Discard any unused drug remaining in the vial.      </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dilution in Infusion Bag</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Calculate the required dose volume (mL) of reconstituted EMRELIS solution based on the prescribed dose. <br/>
                           </item>
                           <item>Withdraw the calculated dose volume (mL) of reconstituted solution from the EMRELIS vial using a sterile syringe. Discard any unused portion remaining in the vial(s).  <br/>
                           </item>
                           <item>Inject the calculated amount of reconstituted solution into 0.9% Sodium Chloride Injection infusion bag so that the final EMRELIS concentration is between 1 mg/mL and 10 mg/mL. Use only 0.9% Sodium Chloride Injection.   <br/>
                           </item>
                           <item>Gently invert the infusion bag to thoroughly mix the solution. Do not shake.<br/>
                           </item>
                           <item>After preparing the dose for infusion, visually inspect the bag content for particulates and discard if present. <br/>
                           </item>
                           <item>If not used immediately, the diluted solution can be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours and an additional 4 hours at room temperature at 9°C to 30°C (48°F to 86°F) until the end of administration. Do not freeze. </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Method of Administration</content>
                        </paragraph>
                        <paragraph>If the prepared infusion solution was stored refrigerated at 2°C to 8°C (36°F to 46°F), allow the solution to reach room temperature prior to administration. </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer by intravenous infusion over 30 minutes using a dedicated infusion line with a 0.20 or 0.22 micron in-line filter made of polyether sulfone (PES), polyvinylidene fluoride (PVDF), or Polyamide (PA). <br/>
                           </item>
                           <item>Do not mix EMRELIS with other drugs or administer other drugs through the same intravenous line.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3__DOSAGE">
               <id root="d87b81b1-8b22-496d-8d36-01f392244221"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3  DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>For injection: 20 mg or 100 mg of telisotuzumab vedotin-tllv as a white to off-white, lyophilized powder in a single-dose vial for reconstitution and further dilution.</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For injection: 20 mg or 100 mg of telisotuzumab vedotin-tllv as a lyophilized powder in a single-dose vial. (<linkHtml href="#_3__DOSAGE">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4__CONTRAINDICATIONS">
               <id root="366df796-4bf3-4388-86b6-05e8fe8a7381"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4  CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#_4__CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_5__WARNINGS">
               <id root="c24bc7b7-daec-4ca3-824e-2a35c652d0c5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5  WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Peripheral Neuropathy</content>: Monitor patients for new or worsening peripheral neuropathy. Withhold, reduce the dose, or permanently discontinue EMRELIS based on the severity. (<linkHtml href="#_5_1_Peripheral_Neuropathy">5.1</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">I</content>
                              <content styleCode="underline">nterstitial Lung Disease (ILD)/</content>
                              <content styleCode="underline">Pneumonitis</content>: Severe, life-threatening or fatal ILD/pneumonitis may occur. Withhold or permanently discontinue EMRELIS based on the severity. (<linkHtml href="#_5_2_Interstitial_Lung">5.2</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Ocular Surface Disorders</content>: Monitor patients for signs or symptoms of ocular surface disorders, including vision changes. Withhold or permanently discontinue EMRELIS based on the severity. (<linkHtml href="#_5_3_Ocular_Surface">5.3</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Infusion</content>
                              <content styleCode="underline">-</content>
                              <content styleCode="underline">Related Reactions</content>
                              <content styleCode="underline"> (IRR)</content>: Monitor patients for IRR. Withhold, reduce the rate of infusion, or permanently discontinue EMRELIS based on the severity. For patients who experience IRR, administer premedications prior to subsequent infusions. (<linkHtml href="#_5_4_Infusion_Related_Reactions">5.4</linkHtml>) <br/>
                           </item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise patients about the potential risk to a fetus and to use effective contraception. (<linkHtml href="#_5_5_Embryo_Fetal_Toxicity">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Peripheral_Neuropathy">
                     <id root="6d04c920-8177-4072-b27a-8bdf761f60e5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Peripheral Neuropathy</content>
                     </title>
                     <text>
                        <paragraph>EMRELIS can cause peripheral neuropathy, including peripheral sensory neuropathy and peripheral motor neuropathy.</paragraph>
                        <paragraph>In the safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)], </content>peripheral neuropathy occurred in 51% of patients treated with EMRELIS, including Grade 3 in 11%. These adverse reactions included peripheral sensory neuropathy in 45% of patients and peripheral motor neuropathy in 9%. The median time to onset of peripheral neuropathy was 105 days (range: 1 to 472 days). Peripheral neuropathy led to permanent discontinuation of EMRELIS in 13% of patients. The median time to onset of peripheral neuropathy leading to treatment discontinuation was 249 days (range: 57 to 519 days). Of the 7 patients with motor neuropathy ongoing as of their last dose of EMRELIS, 6 had persistent Grade 1 or 2 symptoms 30 days after their last dose. </paragraph>
                        <paragraph>Monitor patients for signs and symptoms of new or worsening peripheral neuropathy such as hypoesthesia, hyperesthesia, paresthesia, a burning sensation, neuropathic pain, or muscle weakness. Withhold, reduce the dose or permanently discontinue EMRELIS based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Interstitial_Lung">
                     <id root="6ebc78a7-5c66-43a7-b1a5-736f06f17ea3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Interstitial Lung Disease</content>
                        <content styleCode="bold">/Pneumonitis</content>
                     </title>
                     <text>
                        <paragraph>EMRELIS can cause severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis.</paragraph>
                        <paragraph>In the safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)],</content> ILD/pneumonitis occurred in 10% of patients treated with EMRELIS, including Grade 3 in 3% and Grade 4 in 0.6%. There were 3 fatal cases of ILD/pneumonitis in patients who received EMRELIS. The median time to onset of ILD/pneumonitis was 48 days (range: 23 to 85 days). ILD/pneumonitis led to permanent discontinuation of EMRELIS in 7% of patients. The median time to onset of ILD/pneumonitis leading to treatment discontinuation was 46 days (range: 23 to 85 days).</paragraph>
                        <paragraph>Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD/pneumonitis. Withhold or permanently discontinue EMRELIS based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content> </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Ocular_Surface">
                     <id root="e67a779a-a336-4394-acac-93479466e131"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 </content>
                        <content styleCode="bold">Ocular Surface Disorders</content>
                     </title>
                     <text>
                        <paragraph>EMRELIS can cause ocular surface disorders including blurred vision, visual impairment, keratitis, and dry eye.</paragraph>
                        <paragraph>In the safety population <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)],</content> ocular surface disorders occurred in 25% of patients treated with EMRELIS. The most common ocular surface disorders were blurred vision (15%), keratitis (11%), and dry eye (5%). Grade 3 ocular surface disorders occurred in 1.2% of patients [blurred vision (1.2%), and keratitis (0.6%)]. The median time to onset of ocular surface disorders was 47 days (range: 1 to 319 days). </paragraph>
                        <paragraph>Monitor patients for ocular surface disorders during treatment with EMRELIS. Withhold EMRELIS and refer patients to an eye care professional for an ophthalmic examination and treatment for patients who develop Grade ≥2 ocular toxicity. Withhold or permanently discontinue EMRELIS based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_Infusion_Related_Reactions">
                     <id root="89eed39b-2dad-4b12-b8ff-692387edaa0d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Infusion</content>-<content styleCode="bold">Related Reactions</content>
                     </title>
                     <text>
                        <paragraph>EMRELIS can cause infusion-related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, chills, nausea, chest discomfort, and hypotension. The median time to onset of IRR was 28 days (range: 1 to 43 days). </paragraph>
                        <paragraph>In the safety population, <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1__Clinical">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                           <content styleCode="italics">,</content>  IRR occurred in 3% of patients treated with EMRELIS including Grade 3 in 1.2% and Grade 4 in 0.6%. IRR led to permanent discontinuation of EMRELIS in 0.6% of patients.</paragraph>
                        <paragraph>Monitor patients for signs and symptoms of infusion reactions during EMRELIS infusion. Withhold, reduce the rate of infusion, or permanently discontinue EMRELIS based on severity <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                           <content styleCode="italics"> </content>For patients who experience IRR, administer premedications prior to subsequent infusions.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Embryo_Fetal_Toxicity">
                     <id root="fca1998f-88d6-4a96-abf9-589d7d8e1816"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold"> Embryo-Fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on the mechanism of action and findings in animals, EMRELIS can cause fetal harm when administered to a pregnant woman. The small molecule component of EMRELIS, MMAE, administered to rats caused adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities, at exposures similar to those occurring clinically at the recommended dose.</paragraph>
                        <paragraph>Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with EMRELIS and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with EMRELIS and for 4 months after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1__Pregnancy">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_3__Females">8.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">and Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_1__Mechanism">12.1</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c0bd38de-24cc-4768-a7e3-ce7ab1145810"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6  ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Peripheral Neuropathy <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Peripheral_Neuropathy">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Interstitial Lung Disease (ILD)/Pneumonitis <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Interstitial_Lung">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Ocular Surface Disorders <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Ocular_Surface">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Infusion-Related Reactions (IRR) <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_4_Infusion_Related_Reactions">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥20%) were peripheral neuropathy, fatigue, decreased appetite, and peripheral edema. (<linkHtml href="#_6_1__Clinical">6.1</linkHtml>)</paragraph>
                        <paragraph>The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocytes, increased glucose, increased alanine aminotransferase, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin and decreased calcium. (<linkHtml href="#_6_1__Clinical">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1__Clinical">
                     <id root="1ace3871-b41d-4716-9502-899eb40d8b0f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1  Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">LUMINOSITY</content>
                        </paragraph>
                        <paragraph>The safety population described in <linkHtml href="#_5__WARNINGS">WARNINGS AND PRECAUTIONS</linkHtml> and below reflects exposure to EMRELIS in 168 patients with locally advanced or metastatic EGFR wild-type non-squamous NSCLC with c-Met protein overexpression who received EMRELIS as a single agent administered at 1.9 mg/kg intravenously every 2 weeks<content styleCode="italics"> </content>in the LUMINOSITY study <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14__CLINICAL">14</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content> Among patients who received EMRELIS, 42% were exposed for 6 months or longer and 11% were exposed for greater than one year.  </paragraph>
                        <paragraph>The median age of patients who received EMRELIS was 64.5 years (range: 33 to 83 years); 70% were male; 65% were White; 1.8% were Black or African American, 33% were Asian; and 0.6% were of Hispanic or Latino ethnicity.  </paragraph>
                        <paragraph>Serious adverse reactions occurred in 35% of patients. Serious adverse reactions occurring in  ≥2% of patients included ILD/pneumonitis (5%), pneumonia (5%), peripheral neuropathy (3.6%), and pleural effusion (2.4%). Fatal adverse reactions occurred in 5% of patients who received EMRELIS, including ILD/pneumonitis (1.8%), pneumonia (1.2%), sudden death (1.2%), noninfectious endocarditis (0.6%) and myocardial infarction (0.6%).</paragraph>
                        <paragraph>Permanent discontinuations of EMRELIS due to adverse reactions occurred in 30% of patients. Adverse reactions which resulted in permanent discontinuation of EMRELIS in ≥2% included peripheral neuropathy and ILD/pneumonitis.</paragraph>
                        <paragraph>Dosage interruptions due to adverse reactions occurred in 44% of patients. Adverse reactions which required dosage interruption in ≥2% of patients included peripheral neuropathy, fatigue, pneumonia, increased ALT, blurred vision, COVID-19, ILD/pneumonitis, and keratitis. </paragraph>
                        <paragraph>Dose reductions due to adverse reactions occurred in 28% of patients. Adverse reactions which required dose reductions in ≥2% of patients included peripheral neuropathy, fatigue, and keratitis.</paragraph>
                        <paragraph>The most common adverse reactions (≥20%) were peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.</paragraph>
                        <paragraph>The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocytes, increased glucose, increased ALT, increased gamma glutamyl transferase, decreased phosphorus, decreased sodium, decreased hemoglobin and decreased calcium.</paragraph>
                        <paragraph>Table 5 summarizes the adverse reactions in LUMINOSITY.  </paragraph>
                        <table>
                           <caption>Table 5. Adverse Reactions (≥10%) in Patients with EGFR Wild-Type Non-squamous NSCLC with c-Met Protein Overexpression in LUMINOSITY</caption>
                           <col width="406"/>
                           <col width="116"/>
                           <col width="115"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">EMRELIS</content>
                                    <br/>
                                    <content styleCode="bold">(N=168)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule " valign="bottom"/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <sup>1</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule " align="center"/>
                                 <td styleCode="Toprule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Peripheral neuropathy<sup>2</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">51</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule " colspan="2">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Fatigue<sup>2</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Peripheral edema<sup>2</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule " valign="bottom" align="center"/>
                                 <td styleCode="Toprule Rrule " valign="bottom" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Decreased appetite</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule ">
                                    <content styleCode="bold">Eye disorders</content>
                                 </td>
                                 <td styleCode="Toprule " align="center"/>
                                 <td styleCode="Toprule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">  </content>Blurred vision<sup>3</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">  </content>Keratitis<sup>4</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Pneumonia<sup>2</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule " colspan="2">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Rrule " valign="bottom" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   ILD/pneumonitis<sup>2</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <sup>1</sup>Events were graded using NCI CTCAE version 4.03.<br/>
                                    <sup>2</sup>Grouped term.<br/>
                                    <sup>3</sup>Includes vision blurred, visual acuity reduced, visual impairment.<br/>
                                    <sup>4</sup>Includes corneal cyst, corneal disorder, corneal erosion, corneal edema, corneal opacity, keratitis, keratitis interstitial, punctate keratitis.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other clinically relevant adverse reactions in &lt;10% of patients who received EMRELIS included arthralgia,<content styleCode="bold"> </content>dizziness, dry eye, infusion-related reaction and photophobia.</paragraph>
                        <paragraph>Table 6 presents laboratory abnormalities in LUMINOSITY.</paragraph>
                        <table>
                           <caption>Table 6. Select Laboratory Abnormalities (≥10%) that Worsened from Baseline in Patients with EGFR Wild-Type Non-squamous NSCLC with c-Met Protein Overexpression in LUMINOSITY</caption>
                           <col width="298"/>
                           <col width="126"/>
                           <col width="144"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Laboratory </content>
                                    <content styleCode="bold">Abnormality</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">EMRELIS</content>
                                    <br/>
                                    <content styleCode="bold">(N=168)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Albumin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">61</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Glucose increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">58</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Calcium decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">47</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Alanine transaminase increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Gamma glutamyl transferase increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Aspartate aminotransferase increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">34</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Phosphorus decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Sodium decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Alkaline phosphatase increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Creatinine increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Potassium decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Magnesium decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Glucose decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Magnesium increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Lymphocytes decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">37</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">35</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">White blood cells decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Percentages were calculated using patients with worsening laboratory values from baseline and the number of patients with both baseline and post-treatment measurements as the denominator.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b4233d46-890b-410d-bb26-6f3dff8683b1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7  DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">S</content>
                           <content styleCode="underline">trong CYP3A </content>
                           <content styleCode="underline">I</content>
                           <content styleCode="underline">nhibitors</content>: concomitant use with EMRELIS may increase the AUC of MMAE. Monitor for increased risk of adverse reactions to EMRELIS. (<linkHtml href="#_7_1__Effect">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1__Effect">
                     <id root="8bab8bf5-3d33-4638-9cd8-c61edd42cf82"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold"> Effect of Other Drugs on </content>
                        <content styleCode="bold">EMRELIS</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Strong CYP3A Inhibitors</content>
                        </paragraph>
                        <paragraph>Concomitant use with strong CYP3A inhibitors may increase unconjugated MMAE AUC <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3__Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>, which may increase the risk of EMRELIS adverse reactions. Monitor patients for adverse reactions when EMRELIS is given concomitantly with strong CYP3A inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b7b2399a-d8b2-451e-82f4-efc25056b806"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8  USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250514"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Severe or Moderate </content>
                              <content styleCode="underline">Hepatic </content>
                              <content styleCode="underline">I</content>
                              <content styleCode="underline">mpairment</content>: Avoid use of EMRELIS. (<linkHtml href="#_8_6__Hepatic">8.6</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#_8_2__Lactation">8.2</linkHtml>)<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Infertility</content>: May impair fertility. (<linkHtml href="#_8_3__Females">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1__Pregnancy">
                     <id root="bf8c026a-364f-43c6-9dbb-161229e7265c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1  Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <content styleCode="underline"> </content>
                        </paragraph>
                        <paragraph>Based on the mechanism of action and findings in animals, EMRELIS can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_1__Mechanism">12.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. There are no available human data on EMRELIS use in pregnant women to inform a drug-associated risk. In an animal reproduction study, administration of the small molecule component of EMRELIS, MMAE, to pregnant rats during organogenesis resulted in embryo-fetal mortality and structural abnormalities at exposures similar to the clinical exposure at the recommended dose <content styleCode="italics">[see </content>
                           <content styleCode="italics">Data</content>
                           <content styleCode="italics">]</content>. Advise patients of the potential risks to a fetus.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>No embryo-fetal development studies in animals have been performed with telisotuzumab vedotin-tllv. In an embryo-fetal development study in pregnant rats, administration of two intravenous doses of MMAE, the small molecule component of EMRELIS, on gestational days 6 and 13 caused embryo-fetal mortality and structural abnormalities, including protruding tongue, agnathia, malrotated limbs, and gastroschisis compared to controls at a dose of 0.2 mg/kg (approximately 2 times the human area under the curve [AUC] at the recommended dose).</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_2__Lactation">
                     <id root="ad0053f0-2d63-4bb3-a53d-5772df3ac4cb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2  Lactation </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There are no data on the presence of telisotuzumab vedotin-tllv or MMAE in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with EMRELIS and for 1 month after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_3__Females">
                     <id root="fd188c7a-92e8-49cf-8a5b-b287b476df71"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77291-3" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>
                        <content styleCode="bold">8.3  Females and Males of Reproductive Potential   </content>
                     </title>
                     <text>
                        <paragraph>EMRELIS can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see </content>
                           <content styleCode="italics">Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1__Pregnancy">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating EMRELIS treatment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females </content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with EMRELIS and for 2 months after the last dose. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males </content>
                        </paragraph>
                        <paragraph>Based on genotoxicity findings, advise male patients with female partners of reproductive potential to use effective contraception during treatment with EMRELIS and for 4 months after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Based on findings in animal studies with MMAE-containing antibody-drug conjugates (ADCs), EMRELIS may impair female fertility. The effect on fertility is reversible <content styleCode="italics">[see Nonclinical Toxicology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_13_1__Carcinogenesis_">13.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on findings from animal studies, EMRELIS may impair male fertility. The reversibility of this effect is unknown <content styleCode="italics">[see Nonclinical Toxicology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_13_1__Carcinogenesis_">13.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="06356ad8-27f9-420e-ae1a-dc96804ad66e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4  Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness of EMRELIS have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e9eea1c3-b4af-4113-8508-2ed9c5745c72"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5  Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of the 168 patients with previously treated EGFR wild-type non-squamous NSCLC with c-Met protein overexpression treated with EMRELIS in LUMINOSITY, 50% were ≥65 years of age and 12% were ≥75 years of age. No overall differences in safety or effectiveness were observed between older and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_6__Hepatic">
                     <id root="a2d0fac3-1846-476d-9e3b-ab850f51f8e3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.6  </content>
                        <content styleCode="bold">Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>Avoid use of EMRELIS in patients with moderate or severe hepatic impairment (total bilirubin &gt;1.5 x ULN and any AST).</paragraph>
                        <paragraph>Patients with moderate or severe hepatic impairment are likely to have increased exposure to MMAE, which may increase the risk of adverse reactions. EMRELIS has not been studied in patients with moderate or severe hepatic impairment.</paragraph>
                        <paragraph>No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin ≤ULN and AST &gt;ULN or total bilirubin &gt;ULN and ≤1.5 x ULN and any AST) <content styleCode="italics">[see </content>
                           <content styleCode="italics">Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3__Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="40c78630-6e68-4877-a870-7305924ff889"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11  DESCRIPTION </content>
               </title>
               <text>
                  <paragraph>Telisotuzumab vedotin-tllv is a c-Met directed antibody-drug conjugate (ADC) comprised of a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody conjugated to the small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable valine-citrulline (vc) linker. The antibody is produced in a mammalian cell line (Chinese hamster ovary) and the drug-linker is produced by chemical synthesis. Each monoclonal antibody molecule carries an average of 3 MMAE molecules. Telisotuzumab vedotin-tllv has an approximate molecular weight of 152 kDa.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>EMRELIS (telisotuzumab vedotin-tllv) for injection is a sterile, white to off-white, preservative-free, lyophilized powder in a single-dose vial for reconstitution and dilution prior to intravenous infusion. EMRELIS is supplied as 20 mg per vial or 100 mg per vial and requires reconstitution with Sterile Water for Injection, USP (1.1 mL and 5.2 mL, respectively) to obtain a concentration of 20 mg/mL <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_4_Recommended_Premedications">2.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Following reconstitution, each mL delivers 20 mg of telisotuzumab vedotin-tllv, and histidine (2.33 mg), polysorbate 80 (0.10 mg), sucrose (70.0 mg), and Water for Injection. Hydrochloric acid was added to adjust the pH to 6.0. </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>Telisotuzumab vedotin-tllv is a c-Met directed antibody-drug conjugate (ADC) comprised of a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody conjugated to the small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable valine-citrulline (vc) linker. The antibody is produced in a mammalian cell line (Chinese hamster ovary) and the drug-linker is produced by chemical synthesis. Each monoclonal antibody molecule carries an average of 3 MMAE molecules. Telisotuzumab vedotin-tllv has an approximate molecular weight of 152 kDa.</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="emrelis---teliso-v-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b93dcebb-ca16-499d-bbac-dde812557892"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12  CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="_12_1__Mechanism">
                     <id root="a5e51b67-c684-486f-a528-ba76d042b72b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">  </content>
                        <content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Telisotuzumab vedotin-tllv is a c-Met-directed antibody drug conjugate (ADC). The antibody is a humanized IgG1κ directed against c-Met, the cell surface receptor for hepatocyte growth factor. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease cleavable linker. Following binding to c-Met-expressing cells, telisotuzumab vedotin-tllv undergoes internalization and intracellular cleavage of MMAE. MMAE disrupts the microtubule network of actively dividing cells, subsequently inducing cell cycle arrest and apoptotic cell death. Telisotuzumab vedotin-tllv exhibited antitumor activity in xenograft models of NSCLC.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="28420042-080a-4edd-b2ac-3a1ace68dff4"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
                        <content styleCode="bold">  </content>
                        <content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exposure</content>
                           <content styleCode="underline"> Response Relationships</content>
                        </paragraph>
                        <paragraph>Exposure-response relationships for efficacy and time course of pharmacodynamic response have not been fully characterized.</paragraph>
                        <paragraph>Higher telisotuzumab vedotin-tllv exposure was associated with increased rates of Grade 3 peripheral neuropathy, and Grades 2 and 3 ocular surface disorders. Higher unconjugated MMAE exposure was associated with increased rates of Grade ≥3 adverse reactions and fatal adverse reactions.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>There is insufficient information to characterize the effect of telisotuzumab vedotin-tllv on the QT interval.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3__Pharmacokinetics">
                     <id root="57494d89-dbb1-47b1-8d14-e5f338102f7a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3  Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>The exposure parameters of telisotuzumab vedotin-tllv (ADC) and unconjugated MMAE (cytotoxic component of EMRELIS) are summarized in Table 7. The plasma exposure of the ADC and unconjugated MMAE increased proportionally over a dose range of 1.2 to 3.3 mg/kg (0.64 to 1.7 times the approved recommended dose). ADC time to maximum plasma concentrations (Tmax) occurs at the end of intravenous infusion while MMAE Tmax occurs approximately 5 days after EMRELIS administration. Minimal accumulation of the ADC or MMAE occurs.</paragraph>
                        <table>
                           <caption>Table 7. Exposure Parameters of Telisotuzumab Vedotin-tllv (ADC) and Unconjugated MMAE at EMRELIS 1.9 mg/kg Every 2 Weeks</caption>
                           <col width="114"/>
                           <col width="166"/>
                           <col width="234"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">ADC</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Unconjugated MMAE</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">C<sub>max </sub>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29 (43) µg/mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.2 (53) ng/mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">AUC<sub>0-</sub>
                                    <sub>tau</sub>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2,130 (55) µg∙hr/mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">405 (64) ng∙hr/mL</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>C<sub>max</sub> = maximum concentration </paragraph>
                        <paragraph>AUC<sub>0-</sub>
                           <sub>tau</sub>
                           <sub> </sub>= area under the concentration-time curve from time zero to 14 days (2 weeks)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The estimated volume of distribution is 3.4 L (16.5%CV) for telisotuzumab vedotin-tllv. </paragraph>
                        <paragraph>MMAE plasma protein binding ranges from 68% to 82% <content styleCode="italics">in vitro</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The elimination half-life is approximately 3 days for the ADC and approximately 4 days for MMAE. The estimated clearance (CL) is 1.3 L/day (31.5%CV) for the ADC and 76 L/day (52.1%CV) for MMAE.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Telisotuzumab vedotin-tllv catabolism has not been studied in humans; however, it is expected to undergo catabolism to small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites. MMAE is metabolized primarily by CYP3A4.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of the ADC or unconjugated MMAE were observed based on age (30 to 87 years), sex, race (65% White, 32% Asian, and 3% Black), body weight (34 to 144 kg), mild or moderate renal impairment (CLcr 30 to 89 mL/min, estimated by Cockcroft-Gault), or mild hepatic impairment (total bilirubin ≤ULN and AST &gt;ULN or total bilirubin &gt;ULN and ≤1.5 x ULN and any AST). </paragraph>
                        <paragraph>The effect of severe renal impairment (CLcr &lt;30 mL/min), end-stage renal disease with or without dialysis, or moderate to severe hepatic impairment (total bilirubin &gt;1.5 × ULN and any AST) on the pharmacokinetics of telisotuzumab vedotin-tllv or unconjugated MMAE is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches:</content>
                        </paragraph>
                        <paragraph>No clinical studies have evaluated the potential for drug-drug interactions. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A4 Inhibitor: </content>
                        </paragraph>
                        <paragraph>MMAE AUC is predicted to increase by 1.4-fold following concomitant administration of EMRELIS with ketoconazole (a strong CYP3A inhibitor). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Strong CYP3A4 Inducer: </content>
                        </paragraph>
                        <paragraph>MMAE AUC is predicted to decrease by 70% following concomitant administration of EMRELIS with  rifampicin (a strong CYP3A inducer). </paragraph>
                        <paragraph>
                           <content styleCode="italics">Sensitive CYP3A Substrate: </content>
                        </paragraph>
                        <paragraph>No clinically significant difference in the pharmacokinetics of midazolam (a sensitive CYP3A substrate) is predicted when used concomitantly with EMRELIS.</paragraph>
                        <paragraph>
                           <content styleCode="italics underline">In Vitro</content>
                           <content styleCode="underline"> Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cytochrome P450 (CYP) Enzymes: </content>
                        </paragraph>
                        <paragraph>MMAE is a substrate and an inhibitor of CYP3A4/5.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Transporter Systems: </content>
                        </paragraph>
                        <paragraph>MMAE is a substrate of P-glycoprotein (P-gp).</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3dc74d69-abc9-4c80-a0d5-ea21f38aa507"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88830-5" displayName="IMMUNOGENICITY"/>
                     <title>
                        <content styleCode="bold">12.6  Immunogenicity</content>
                     </title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies, including those of EMRELIS or of other telisotuzumab products.</paragraph>
                        <paragraph>Following administration of EMRELIS in LUMINOSITY, 22% (60/269) of patients tested positive for treatment-emergent antibodies against telisotuzumab vedotin-tllv at one or more post-baseline time points. Of those who tested positive for anti-drug antibody, neutralizing antibodies were detected in 38% (23/60) of patients. Development of anti-drug antibodies and neutralizing antibodies resulted in a 17% decrease in clearance of telisotuzumab vedotin-tllv. There are insufficient data to assess whether the observed anti-telisotuzumab vedotin-tllv antibody-associated pharmacokinetic changes affect the safety and effectiveness of EMRELIS.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_13__NONCLINICAL">
               <id root="c0b44c12-c836-4ded-9617-399e58dada88"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13  NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250514"/>
               <component>
                  <section ID="_13_1__Carcinogenesis_">
                     <id root="9e3a9234-66fd-400d-a7cc-8d312055fd85"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Carcinogenicity studies in animals have not been performed with telisotuzumab vedotin-tllv or the small molecule MMAE.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>MMAE was positive for genotoxicity in the <content styleCode="italics">in vivo</content> rat bone marrow micronucleus study through an aneugenic mechanism. MMAE was not mutagenic in the bacterial reverse mutation (Ames) assay or the L5178Y TK<sup>+/-</sup> mouse lymphoma forward mutation assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility studies with telisotuzumab vedotin-tllv or MMAE have not been conducted. However, results of repeat-dose toxicity studies in rats and monkeys indicate the potential for telisotuzumab vedotin-tllv to impair male and female reproductive function and fertility.</paragraph>
                        <paragraph>In a 2-week repeat-dose toxicology study in rats, telisotuzumab vedotin-tllv administered at doses ≥6 mg/kg (≥12 times the human exposure [AUC] at the recommended dose) resulted in decreased number/degeneration of germ cells in the testes largely due to loss of spermatogonia. The reversibility of these findings was not assessed.</paragraph>
                        <paragraph>In a 4-week repeat-dose toxicology study in sexually immature monkeys, telisotuzumab vedotin-tllv administered at doses ≥3 mg/kg (≥4 times the human exposure [AUC] at the recommended dose) resulted in degeneration of granulosa cells and decreased number of tertiary follicles in the ovaries and degeneration/necrosis of endometrial glands in the uterus. There was evidence of reversibility after an 8-week recovery period.</paragraph>
                     </text>
                     <effectiveTime value="20250514"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14__CLINICAL">
               <id root="983ed3b7-eed3-42ee-a37d-ed197e58c240"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14  CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Previously</content>
                     <content styleCode="bold"> Treated EGFR Wild-Type N</content>
                     <content styleCode="bold">on-squamous</content>
                     <content styleCode="bold"> NSCLC with </content>
                     <content styleCode="bold">High</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">c-Met Protein Overexpression </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">LUMINOSITY</content>
                  </paragraph>
                  <paragraph>The efficacy of EMRELIS was evaluated in the LUMINOSITY study (NCT03539536), a multicenter, open-label, single-arm, multi-cohort clinical trial. Eligible patients were required to have locally advanced or metastatic NSCLC with c-Met protein overexpression and treatment with prior systemic therapy (including no more than one line of prior chemotherapy) in the locally advanced or metastatic setting. The study excluded patients who had received radiation therapy to the lungs &lt;6 months prior to enrollment and patients who had a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis within 3 months of the first dose.</paragraph>
                  <paragraph>Patients received EMRELIS at 1.9 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by a blinded independent central review (BICR). An additional efficacy outcome measure was duration of response (DOR) by BICR.</paragraph>
                  <paragraph>The efficacy population included 84 patients with non-squamous, EGFR wild-type NSCLC with high c-Met protein overexpression who had received prior systemic therapy. High c-Met protein overexpression was defined as ≥50% of tumor cells with strong (3+) membrane staining on archival or recent tissue samples by immunohistochemistry (IHC) and was determined by prospective testing at a central laboratory prior to enrollment using the MET (SP44) clinical trial assay (CTA). Of the 84 patients with high c-Met protein overexpression identified by central testing using the CTA, tissue samples from 38/84 (45%) patients were tested retrospectively using the VENTANA MET (SP44) RxDx assay. One sample was unevaluable. Of the 37 samples retested and evaluable, 32 (87%) samples were confirmed to have high c-Met protein overexpression, defined as ≥50% of tumor cells with strong (3+) membrane and/or cytoplasmic staining.</paragraph>
                  <paragraph>The median age was 64 years (range: 38 to 83 years); 75% were male; 61% were White, 1.2% were Black or African American, 38% were Asian; none were of Hispanic or Latino ethnicity. Twenty-five percent had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 and 74% had ECOG PS of 1; 19% were never smokers, 68% were former smokers, and 13% were current smokers; 99% had Stage IV disease; and 19% of patients had previously treated brain metastases. The median number of lines of prior therapies was 1 (range 1 - 3); 73% of patients had one line, 24% had two lines, and 3.6% had three lines of prior systemic therapy; 96% of patients had prior platinum therapy, 82% had prior immunotherapy (anti-PD-1/PD-L1), 6% had prior targeted therapy, and 3.6% had prior MET tyrosine kinase inhibitor therapy.</paragraph>
                  <paragraph>Efficacy results are summarized in Table 8.</paragraph>
                  <table>
                     <caption>Table 8. Efficacy Results in LUMINOSITY for Patients with EGFR Wild-Type Non-squamous NSCLC with High c-Met Protein Overexpression</caption>
                     <col width="393"/>
                     <col width="234"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Efficacy Parameter</content>
                              <content styleCode="bold">   </content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">EMRELIS</content>
                              <br/>
                              <content styleCode="bold">N = </content>
                              <content styleCode="bold">84</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Confirmed </content>
                              <content styleCode="bold">Overall Response Rate</content> <content styleCode="bold">(ORR)</content>, %<br/>(95% CI) </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">35<br/>(24, 46)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">     Complete Response,<br/>%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">     Partial Response,<br/>%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">35</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">
                              <content styleCode="bold">Duration of Response</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <content styleCode="bold">N = 29</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">     Median, months <br/>     (95% CI)</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">7.2<br/>(4.2, 12)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">     DOR ≥6 months,<sup>a</sup> % </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">59</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule ">     DOR ≥12 months,<sup>a</sup>
                              <sup> </sup>%</td>
                           <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">CI=confidence interval; DOR=duration of response<br/>
                              <sup>a</sup>
                              <sup> </sup>Based on observed duration of response in 29 responders.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b15c2035-8e06-41ca-96c3-1bed25148935"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34093-5" displayName="REFERENCES SECTION"/>
               <title>
                  <content styleCode="bold">15  REFERENCES</content>
               </title>
               <text>
                  <paragraph>1. "OSHA Hazardous Drugs." <content styleCode="italics">OSHA</content>. http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8dc02282-2245-4313-9397-1dd76ed1cce2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16  HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>EMRELIS (telisotuzumab vedotin-tllv) for injection is a sterile, preservative-free, white to off-white lyophilized powder, supplied in a glass single-dose vial.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Carton of one 20 mg/vial (NDC 0074-1044-01)<br/>
                     </item>
                     <item>Carton of one 100 mg/vial (NDC 0074-1055-01)</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store refrigerated at 2<sup>o</sup>C to 8<sup>o</sup>C (36<sup>o</sup>F to 46<sup>o</sup>F) in original carton to protect from light. Do not freeze. Do not shake.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Special Handling</content>
                  </paragraph>
                  <paragraph>EMRELIS is a hazardous product. Follow special handling and disposal procedures.<sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a806b2ea-c3a3-446f-abef-72eec0001f64"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17  PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#MEDICATIONGUIDE">Medication Guide</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Peripheral Neuropathy</content>
                  </paragraph>
                  <paragraph>Advise patients that EMRELIS can cause peripheral neuropathy. Advise patients to report to their healthcare provider any new or worsening numbness or tingling of the hands or feet or any muscle weakness <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Peripheral_Neuropathy">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">ILD/Pneumonitis</content>
                  </paragraph>
                  <paragraph>Advise patients that EMRELIS can cause ILD/pneumonitis. Advise patients to immediately report to their healthcare provider any new or worsening respiratory symptoms <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Interstitial_Lung">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ocular Surface Disorders</content>
                  </paragraph>
                  <paragraph>Advise patients that EMRELIS can cause ocular surface disorders. Advise patients to contact their healthcare provider any new or worsening ocular problems or vision changes <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_3_Ocular_Surface">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infusion</content>
                     <content styleCode="underline">-Related Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that EMRELIS can cause infusion-related reactions. Advise patients to immediately contact their healthcare provider if they experience signs and symptoms of infusion reactions, including fever, chills, rash, or breathing problems <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_4_Infusion_Related_Reactions">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise female patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with EMRELIS <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_5_Embryo_Fetal_Toxicity">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">) and Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_1__Pregnancy">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Females and Males of Reproductive Potential</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Advise females of reproductive potential to use effective contraception during treatment and for 2 months after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_8_3__Females">8.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>.<br/>
                     </item>
                     <item>Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_8_3__Females">8.3</linkHtml>
                        </content>
                        <content styleCode="italics">)].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with EMRELIS and for 1 month after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_2__Lactation">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>Advise males and females of reproductive potential that EMRELIS may impair fertility <content styleCode="italics">[see Nonclinical Toxicology</content>
                     <content styleCode="italics"> (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_13__NONCLINICAL">13</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics">].</content>
                  </paragraph>
                  <paragraph>EMRELIS™ [telisotuzumab vedotin-tllv]</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">AbbVie Inc.</content>
                     <br/>North Chicago, IL 60064, U.S.A.<br/>U.S. License No. 1889<br/>© 2025 AbbVie. All rights reserved. <br/>EMRELIS and its design are trademarks of AbbVie Inc.</paragraph>
                  <paragraph>20090524</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="78f4a83c-5e46-47d4-8be0-ffb0e1bee290"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42231-1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table ID="MEDICATIONGUIDE">
                     <col width="396"/>
                     <col width="326"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>EMRELIS™ (EM-rell-is)<br/>(telisotuzumab vedotin-tllv)<br/>for injection, for intravenous use</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What is the most important information I should know about EMRELIS?</content>
                              <br/>
                              <content styleCode="bold">EMRELIS can cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Nerve problems in your hands or feet</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">(peripheral neuropathy). </content>Nerve problems are common during treatment with EMRELIS and can also be severe. Tell your healthcare provider if you develop any new or worsening signs or symptoms of nerve problems, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>numbness<br/>
                                 </item>
                                 <item>tingling<br/>
                                 </item>
                                 <item>burning sensation</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>pain or discomfort<br/>
                                 </item>
                                 <item>muscle weakness<br/>
                                 </item>
                                 <item>difficulty walking</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Lung problems. </content>EMRELIS can<content styleCode="bold"> </content>cause<content styleCode="bold"> </content>lung problems that may be severe, life-threatening or that may lead to death.<content styleCode="bold"> </content>Tell your healthcare provider right away if you develop new or worsening lung symptoms, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>cough<br/>
                                 </item>
                                 <item>trouble breathing or shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever<br/>
                                 </item>
                                 <item>wheezing</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Eye problems.</content> Your healthcare provider may send you to an eye care professional to check your eyes if you develop eye problems. Tell your healthcare provider right away if you develop any new or worsening eye problems or vision changes, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blurred vision<br/>
                                 </item>
                                 <item>dry eyes<br/>
                                 </item>
                                 <item>sensitivity to light</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>eye pain or swelling<br/>
                                 </item>
                                 <item>eye redness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infusion-related reactions. </content>EMRELIS can cause infusion reactions that can be severe<content styleCode="bold"> </content>or life-threatening. Tell your healthcare provider right away if you develop any signs and symptoms of infusion reactions, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>itching or rash<br/>
                                 </item>
                                 <item>shortness of breath or wheezing<br/>
                                 </item>
                                 <item>flushing<br/>
                                 </item>
                                 <item>chest discomfort<br/>
                                 </item>
                                 <item>fever</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>back pain<br/>
                                 </item>
                                 <item>chills<br/>
                                 </item>
                                 <item>headache<br/>
                                 </item>
                                 <item>nausea or vomiting<br/>
                                 </item>
                                 <item>feel like passing out</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <content styleCode="bold">Getting medical treatment right away may help keep these problems from becoming more serious. </content>Your healthcare provider will check you for these problems during your treatment with EMRELIS and may provide treatment for your side effects. Your healthcare provider may also need to change your dose, temporarily stop, or completely stop treatment with EMRELIS if you have severe side effects.<br/>See<content styleCode="bold"> “What are the possible side effects of EMRELIS?” </content>for more information about side effects.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What is EMRELIS?</content>
                              <br/>EMRELIS is a prescription medicine used to treat adults with non-squamous non-small cell lung cancer (NSCLC):<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>that has spread to areas near the lungs (locally advanced) or to other parts of the body (metastatic), <content styleCode="bold">and</content>
                                    <br/>
                                 </item>
                                 <item>whose tumors have high c-Met protein overexpression, <content styleCode="bold">and</content>
                                    <br/>
                                 </item>
                                 <item>who have received a prior treatment.</item>
                              </list>Your healthcare provider will perform a test to make sure EMRELIS is right for you.<br/>It is not known if EMRELIS is safe and effective in children.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">Before receiving EMRELIS, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have a history of nerve problems<br/>
                                 </item>
                                 <item>have lung or breathing problems other than your lung cancer<br/>
                                 </item>
                                 <item>have eye problems<br/>
                                 </item>
                                 <item>have liver problems<br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. EMRELIS can harm your unborn baby.</item>
                              </list>
                              <content styleCode="bold">Females who are able to become pregnant:</content>
                              <br/>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Your healthcare provider should do a pregnancy test before you start treatment with EMRELIS.<br/>
                                 </item>
                                 <item>You should use effective birth control (contraception) during treatment and for 2 months after your last dose of EMRELIS.<br/>
                                 </item>
                                 <item>Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EMRELIS.</item>
                              </list>
                              <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                              <br/>
                              <list listType="unordered" styleCode="Circle">
                                 <item>You should use an effective birth control during treatment and for 4 months after your last dose of EMRELIS.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if EMRELIS passes into your breast milk. Do not breastfeed during treatment with EMRELIS and for 1 month after the last dose.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking certain medicines with EMRELIS may increase your risk of side effects.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">How will I receive EMRELIS?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Your healthcare provider will give you EMRELIS into your vein through an intravenous (IV) line over 30 minutes.<br/>
                                 </item>
                                 <item>EMRELIS is given 1 time every 2 weeks.<br/>
                                 </item>
                                 <item>Your healthcare provider will decide how many infusions of EMRELIS you will receive.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What are the possible side effects of EMRELIS?</content>
                              <br/>
                              <content styleCode="bold">EMRELIS can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See<content styleCode="bold"> “What is the most important information I should know about EMRELIS?”</content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of </content>
                              <content styleCode="bold">EMRELIS</content>
                              <content styleCode="bold"> include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>feeling tired</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>swelling in the feet, ankles, legs or hands</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>decreased appetite</item>
                              </list>
                           </td>
                           <td styleCode="Rrule "/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <content styleCode="bold">The most common severe abnormal </content>
                              <content styleCode="bold">laboratory test results with</content>
                              <content styleCode="bold"> EMRELIS include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>decreased white blood cell counts<br/>
                                 </item>
                                 <item>increased blood sugar levels<br/>
                                 </item>
                                 <item>increased blood liver enzyme levels<br/>
                                 </item>
                                 <item>decreased blood phosphorus levels</item>
                              </list>
                           </td>
                           <td styleCode="Rrule ">
                              <list listType="unordered" styleCode="Disc">
                                 <item>decreased blood sodium levels<br/>
                                 </item>
                                 <item>decreased red blood cell counts<br/>
                                 </item>
                                 <item>decreased blood calcium levels</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="2">EMRELIS may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.<br/>These are not all the possible side effects of EMRELIS.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">General information about the safe and effective use of EMRELIS.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about EMRELIS that is written for healthcare professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="2">
                              <content styleCode="bold">What are the ingredients in EMRELIS?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> telisotuzumab vedotin-tllv<br/>
                              <content styleCode="bold">Inactive ingredients: </content>histidine, polysorbate 80, sucrose. Hydrochloric acid added to adjust the pH.<br/>Manufactured by: AbbVie Inc., North Chicago, IL 60064, USA<br/>U.S. License Number: 1889<br/>Marketed by: AbbVie Inc., North Chicago, IL 60064 U.S.A.<br/>©2025 AbbVie. All rights reserved. <br/>EMRELIS and its design are trademarks of AbbVie Inc.<br/>For more information, go to <content styleCode="underline">www.EMRELIS.com</content> or call 1-844-859-5760.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.              Issued: 05/2025</paragraph>
                  <paragraph>20090524</paragraph>
               </text>
               <effectiveTime value="20250514"/>
            </section>
         </component>
         <component>
            <section>
               <id root="af7c2a9b-4034-474b-aca0-d221acb9eb82"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0074-1044-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Emrelis™</content>
                  </paragraph>
                  <paragraph>(telisotuzumab vedotin-tllv)</paragraph>
                  <paragraph>For Injection</paragraph>
                  <paragraph>20 mg per vial</paragraph>
                  <paragraph>
                     <content styleCode="bold">Hazardous Drug</content>
                  </paragraph>
                  <paragraph>For Intravenous Infusion after reconstitution</paragraph>
                  <paragraph>and dilution</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <paragraph>Dispense the enclosed Medication Guide to </paragraph>
                  <paragraph>each patient</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000002"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM02000002">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0074-1044-01
Emrelis™
(telisotuzumab vedotin-tllv)
For Injection
20 mg per vial
Hazardous Drug
For Intravenous Infusion after reconstitution
and dilution
Single-Dose Vial
Discard Unused Portion
Dispense the enclosed Medication Guide to 
each patient
Rx Only
abbvie

</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="emrelis---teliso-v-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="06aa0e15-078f-498b-b2b9-33f27547c0c6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>NDC 0074-1055-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Emrelis™</content>
                  </paragraph>
                  <paragraph>(telisotuzumab vedotin-tllv)</paragraph>
                  <paragraph>For Injection</paragraph>
                  <paragraph>100 mg per vial</paragraph>
                  <paragraph>
                     <content styleCode="bold">Hazardous Drug</content>
                  </paragraph>
                  <paragraph>For Intravenous Infusion after reconstitution</paragraph>
                  <paragraph>and dilution</paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <paragraph>Dispense the enclosed Medication Guide to </paragraph>
                  <paragraph>each patient</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">abbvie</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000003"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250514"/>
               <component>
                  <observationMedia ID="MM02000003">
                     <text>PRINCIPAL DISPLAY PANEL
NDC 0074-1055-01
Emrelis™
(telisotuzumab vedotin-tllv)
For Injection
100 mg per vial
Hazardous Drug
For Intravenous Infusion after reconstitution
and dilution
Single-Dose Vial
Discard Unused Portion
Dispense the enclosed Medication Guide to 
each patient
Rx Only
abbvie

</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="emrelis---teliso-v-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>